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The purpose of this research was to test the hypothesis that starch-entrapped microspheres would produce favourable fermentation profiles and
microbial shifts during in vitro fermentation with the faecal microbiota from patients with inflammatory bowel disease (IBD). In vitro fermentation
was carried out using a validated, dynamic, computer-controlled model of the human colon (Toegepast Natuurwetenschappelijk Onderzoek gastrointestinal model-2) after inoculation with pooled faeces from healthy individuals, patients with inactive IBD (Crohn’s disease (CD)) or patients
with active IBD (ulcerative colitis (UC)). Starch-entrapped microspheres fermented more slowly and produced more butyrate than fructooligosaccharides (FOS) when fermented with the faecal microbiota from patients with active UC. When fermented with the microbiota from
patients with inactive CD, starch-entrapped microspheres also fermented more slowly but produced similar amounts of butyrate compared with
FOS. Starch-entrapped microspheres showed a greater ability to maintain a low pH during simulated-distal colon conditions compared with
FOS. After fermentation with the microbiota from inactive CD patients, starch-entrapped microspheres resulted in lower concentrations of
some potentially harmful gut bacteria, included in Bacteroides, Enterococcus, Fusobacterium and Veillonella, compared with FOS. These findings
suggest that slow fermenting starch-entrapped microspheres may induce a favourable colonic environment in patients with IBD through high
butyrate production, maintenance of low pH in the distal colon and inhibition of the growth of potentially harmful bacteria.
Butyrate: Ulcerative colitis: Crohn’s disease: Encapsulation: Colon: Bacteria

Ulcerative colitis (UC) and Crohn’s disease (CD), collectively
known as inflammatory bowel disease (IBD), are chronic
diseases with unknown aetiologies. The clinical course is
characterised by episodes of flare-up, i.e., patients are symptomatic and exhibit active intestinal inflammation and tissue
injury, followed by periods of remission, i.e., patients are
asymptomatic and display no active intestinal inflammation
or tissue injury. There is evidence that the active inflammation experienced in IBD is, at least in part, due to an
inappropriate and dysregulated immune response to luminal
gut microbiota.
The luminal-associated microbiota move through the large
bowel with peristaltic movements and appear in the faeces,
while mucosa-associated microbiota are static and are present
at the mucous interface between the epithelium and lumen(1).
Harper et al. (2) demonstrated that a small bowel effluent
(containing luminal bacteria) introduced into the defunctioned
colon of patients with CD treated by loop ileostomy was
far more pro-inflammatory than a (sterile) ultrafiltrate of the

effluent. Additionally, diversion of the intestinal luminal
contents into the surgically excluded ileum of patients with
CD induced inflammation in previously unaffected regions(3).
Thus, gut microbiota appear to play a key pathogenic role in
both initiation and clinical course of IBD.
The luminal microbiota community can be simplistically
divided into helpful/beneficial and harmful bacteria. ‘Helpful’
bacteria inhibit the growth of harmful bacteria, beneficially
stimulate the immune system, induce production of SCFA,
aid in digestion and absorption of nutrients and synthesise
vitamins(4). ‘Harmful’ bacteria induce protein purification,
inhibit production of SCFA and promote growth of injurious
bacteria or production of their pro-inflammatory and
injurious products. Thus, factors that enhance the establishment of helpful bacteria in the gut lumen, while inhibiting
the harmful ones, may prevent initiation and/or progression
of the intestinal inflammatory cascade experienced in IBD
patients during disease flare-up and, therefore, induce and
maintain remission.

Abbreviations: CD, Crohn’s disease; FOS, fructo-oligosaccharides; IBD, inflammatory bowel disease; TIM-2, Toegepast Natuurwetenschappelijk Onderzoek
gastro-intestinal model-2; UC, ulcerative colitis.
* Corresponding author: Bruce R. Hamaker, fax þ 1 765 494 7953, email hamakerb@purdue.edu
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Fermentation of starch-entrapped microspheres

Maintenance of a healthy gut microbiota relies on indigestible carbohydrates or dietary fibre. Under adequate dietary
fibre intake, gut microbes receive a sufficient supply of
carbohydrate to fulfil energy needs. During saccharolytic
fermentation, bacteria produce SCFA (e.g., acetate, propionate
and butyrate) and gases (e.g. CO2 and hydrogen) and are able
to proliferate. SCFA help maintain a (relatively) low colonic
pH, preventing the growth of potentially harmful bacteria(5).
Acetate and propionate can be absorbed into the blood
stream, and influence glucose and lipid metabolism(6), while
butyrate is utilised almost completely by colonic epithelial
cells and represents their major source of energy(7). With
respect to IBD, butyrate is of particular importance because
it additionally acts as an anti-inflammatory agent(8). Therefore,
it appears that adequate dietary fibre intake is important for
maintaining healthy gut microbiota community and for the
prevention or alleviation of colonic inflammation.
It is important to note, however, that not all dietary fibres
are created equal. Most dietary fibres that can be utilised by
bacteria (i.e., fermentable fibres) are rapidly degraded at the
terminal ileum and caecum, leaving very little carbohydrate
substrate for both luminal and especially mucosal bacteria in
more distal regions of the colon(9). This results in a decrease
in SCFA (and thus an increase in pH) and an increase in
undesirable, even toxic compounds, such as phenol and NH3
in distal regions of the colon(10), resulting in a less healthy
colonic environment. Thus, intake of slowly fermentable
fibres may help increase beneficial fermentative products in
the distal colon and improve colonic health.
We have developed a novel source of dietary fibre, termed
starch-entrapped microspheres, wherein electrostatically
cross-linked alginate forms a web-like structure that is filled
with starch(11). The alginate thus creates a physical barrier
that impedes digestion such that over 90 % of the starch in
uncooked starch-entrapped microspheres remains intact after
simulated upper-gastrointestinal digestion (i.e. mouth,
stomach and small intestine) using an in vitro procedure(12).
Furthermore, this product has shown potential as a slowly
fermentable fibre with high production of butyrate and the
ability to change the colonic microbiota in vitro (12). Thus,
the purpose of this research was to test the hypothesis that
slow fermenting starch-entrapped microspheres would
produce more favourable fermentation profiles and microbial
shifts than a rapidly fermenting fibre, fructo-oligosaccharides
(FOS), during in vitro fermentation with the faecal microbiota
obtained from patients with IBD.

Experimental methods
Fermentation substrates
Starch-entrapped microspheres were made by dissolving
0·2 kg of sodium alginate in 8·8 kg water. One kilogram of
waxy maize starch was then added, and the suspension was
mixed until homogenous. The slurry was then pumped through
an atomiser into 20 l of stirred 4 % (w/v) calcium chloride
dihydrate. The microspheres were then harvested by filtration.
After extensive washing, the microspheres were mixed with
ethanol and filtered again. The ethanol was necessary to
prevent the microspheres from sticking together. The microspheres were allowed to dry in air until the odour of ethanol
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could not be detected (about 4 h) and then moved to a
forced draft oven at 458C to finish drying (about 24 h).
Total starch was determined using a colorimetric method
(Total
Starch
(a-amylase/amyloglucosidase
method),
Megazyme, Wicklow, Ireland) after disruption of the alginate
matrix with a ball mill (Brinkman, Westbury, NY, USA).
Moisture content was measured by loss in weight after
drying in a forced draft oven at 1058C for 18 h. Short-chain
FOS was obtained from Encore Technologies (Plymouth,
MN, USA). As per the manufacturer’s spec sheet, the product
contained 94 % FOS, 0– 4 % glucose and 4–8 % sucrose.
Faeces
Fresh stools were collected from six patients with inactive CD
and six patients with active UC, who had not received antibiotics within the last 4 weeks. CD and UC patients were
selected from the IBD Clinic at Rush University Medical
Center (Chicago, IL, USA). The diagnosis of UC and CD
diseases was made based on established clinical, endoscopic
and histological criteria. Patients with inactive CD had a CD
activity index of ,150, and had no diarrhoea, abdominal
pain or bleeding. Patients with active UC had rectal bleeding,
diarrhoea (liquid stool and stool frequency . 3/d) and friable
and ulcerated rectosigmoid mucosa on their sigmoidoscopy
at the time of stool collection. All the patients were taking
daily 5-aminosalicylic acid, but none were taking prednisone
at the time of stool collection. The healthy controls consisted
of faculty and staff of the university who were not involved in
the study. Faeces were collected in gas-tight bags containing
Anaerocult C (to maintain anaerobosis; Merck, Darmstadt,
Germany), frozen in liquid nitrogen and then stored at
2808C until used for fermentation experiments (approximately 1 month).
To validate our use of frozen stool in fermentation
experiments, we analysed a fresh microbiota and the same
microbiota stored at 2 808C. Microbial composition of the
fresh and frozen microbiotas was checked periodically over
44 weeks of storage using denaturing gradient electrophoresis
as described previously(13). Activity of the fresh and frozen
microbiotas (8 d, 2 808C) was assessed by measuring SCFA
production during in vitro fermentation as described below,
except the total fermentation time was 196 h, and the microbiota were maintained on the standard ileal efflux medium
during the entire experiment rather than switching to the test
carbohydrates after 16 h.
Fermentation
Faeces were defrosted in an anaerobic cabinet, and samples
from six individuals in each of the three categories were
combined to yield a microbiota representative of that group.
The amounts used from each individual were not equal
due to differing amounts of stool collected (Table 1). Pooling
was important to reduce the possibility of anomalous
results(14) due to the highly variable nature of gut microbiota among individuals(15). The faeces were homogenised
with nine volumes of diluted standard ileal efflux medium
(modified from(16); Table 2). Ninety millilitres of this
homogenate were used to inoculate the Toegepast Natuurwetenschappelijk Onderzoek in vitro model of the large
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Table 1. Amount of faecal material used from each donor
Healthy
ID

Inactive CD

Active UC

Faeces (g)*

ID

Faeces (g)

ID

Faeces (g)

23·8
21·0
33·9
44·7
36·6
40·0
200

17
13
20
15
6
25
Total

11·9
32·8
19·1
45·3
35·4
59·0
204

5
2
22
24
10
14
Total

30·5
5·2
22·8
29·2
73·4
44·0
205

1
8
3
4
7
12
Total
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CD, Crohn’s disease; UC, ulcerative colitis; ID, identification.
* Wet weight.

SCFA determination

intestine: the Toegepast Natuurwetenschappelijk Onderzoek
gastro-intestinal model-2 (TIM-2) system (TNO, Zeist, The
Netherlands)(17). This system has been validated against
sudden death individuals(13) and recently investigated using
molecular RNA technology and assessed as closely simulating
the microbiota in the colon(18).
The TIM-2 system was allowed to equilibrate for 16 h after
inoculation, during which time the microbiota (representing
healthy, inactive CD or active UC) were fed a standard ileal
efflux medium (Table 2) at a rate of 2 ml/h (containing 5 g
of carbohydrate per 24 h). After equilibration, the feeding
line was shut off, and the microbiotas were starved for 2 h.
The test period (t ¼ 0 h) was then begun by introducing the
test carbohydrates (starch-entrapped microspheres or FOS)
into the TIM-2 units. Carbohydrates were administered with
a standard ileal efflux medium prepared without the carbohydrates listed in Table 2. FOS was dissolved in the
medium, and starch-entrapped microspheres, due to their
insoluble nature, were administered through a second syringe
that was kept dry. Test carbohydrates were given at a rate of
10 g of fermentable carbohydrate per 24 h for 72 h.
Table 2. Composition of standard ileal efflux medium (SIEM) and
diluted SIEM per litre
Component
Normal maize starch (g)
Bacto peptone (g)
Casein (g)
Tween 80 (g)
Pectin (g)
Xylan (g)
Arabinogalactan (g)
Waxy maize starch (g)
NaCl (g)
MgSO4 (g)
K2HPO4·3H2O (mg)
Haemine (mg)
FeSO4·7H2O (mg)
Cys·HCl (mg)
CaCl2·2H2O (mg)
Bile (mg)
Pantothenic acid (mg)
Nicotinamide (mg)
p-Aminobenzoic acid (mg)
Thiamin (mg)
Biotin (mg)
Menadione (mg)
Vitamin B12 (mg)
Antifoam B (ml)

The bacteria were constantly supplied with carbohydrate;
therefore, this model more closely resembles the proximal
rather than the distal colon. To approximate the distal colon
more closely, during the last 4 h of fermentation (t ¼ 68 –
72 h), the feeding line was shut off, and the pH was monitored
to indicate whether the saccharolytic fermentation continued,
or if the bacteria switched to putrefactive fermentation due
to lack of carbohydrate. Samples were collected every 24 h
for SCFA quantification, and microbial analyses were
performed at the initial (t ¼ 0 h) and final (t ¼ 72 h) times.
Fig. 1 shows a timeline of these events.

SIEM

Diluted SIEM

75·1
70·4
70·4
50·7
9·01
9·01
9·01
9·01
1·35
1·5
751
3
1·5
300
135
117
15
7·51
7·51
6·01
3
1·5
0·751
7·51

39
23·4
23·4
16·9
4·68
4·68
4·68
4·68
0·703
0·390
390
1·56
0·781
156
70·3
78·1
7·81
3·9
3·9
3·12
1·56
0·781
0·39
3·9

For SCFA, lumen or dialysate samples were centrifuged
(12 000 rpm, 5 min). A mixture of formic acid (20 %), methanol and 2-ethyl butyric acid (internal standard, 2 mg/ml in
methanol) was added to the supernatant. A 0·5 ml sample
was injected onto a GC column (Stabilwax-DA, length 15 m,
inner diametre 0·53 mm, film thickness 0·1 mm; Varian
Chrompack, Bergen op Zoom, The Netherlands) in a Chrompack CP9001 GC using an automatic sampler (Chrompack
liquid sampler CP9050; Varian Chrompack)(19).
Microbial analysis
Analysis of the microbiota with the intestinal-chip was
performed at TNO (Zeist, The Netherlands), described by
Inoculate TIM-2 system
–12

Adaptation period
(microbiota-fed
SIEM)

0

Starvation period

Shut off feeding line
Sampling;
turn on feeding line;
begin adding test
carbohydrate

12

Sampling

24

Test period
(microbiota-fed SM
or FOS

36

Sampling

48

60
Shut off feeding line
Sampling

72

Starvation period
(simulated distal
colon conditions)

Fig. 1. Timeline for Toegepast Natuurwetenschappelijk Onderzoek
gastro-intestinal model-2 (TIM-2) experiments; numbers represent hours;
SIEM, standard ileal efflux medium; SM, starch-entrapped microspheres;
FOS, fructo-oligosaccharides.

Fermentation of starch-entrapped microspheres
0

4

20

24

28

44

M

Data analysis
Data were analysed with SAS software (version 9.1;
SAS Institute, Cary, NC, USA) using a mixed model
ANOVA (PROC MIXED). Main effects were microbiota
source (1, healthy; 2, inactive CD; 3, active UC) and carbohydrate source (1, starch-entrapped microspheres; 2, FOS).
For those analyses that included a time element (i.e., comparison between the initial and final times), a time effect (0 and
72 h) was also included. Fisher’s least significant different
test was used to determine significant differences among
treatment combinations. All the treatment combinations were
performed in quadruplicate, except when the active UC
microbiota were fermented with FOS, which were performed
in triplicate.
Ethical approval
The present study was conducted according to the guidelines
laid down in the Declaration of Helsinki and all procedures
involving human subject/patients were approved by the
Institutional Review Board of Rush University Medical
Center. Written informed consent was obtained from all the
subjects/patients.

Fig. 2. Denaturing gradient gel electrophoresis profiles of a fresh faecal
sample (0) and the same faecal sample after frozen storage (2 808C) for 4,
20, 24, 28 and 44 weeks. M, marker.

Moreover, the ratios of SCFA produced during fermentation
(acetate:propionate:butyrate) were not significantly different
for fresh and frozen microbiotas (data not shown).
Previously, others have reported using frozen microbiotas
from animals(21,22). For example, Hervas et al. (22) discovered
that storage of rumen fluid at 2 188C for 24 h did not affect
fermentation parameters when starch and cellulose were
fermented; although average fermentation rate and the extent
of polysaccharide degradation were affected, when barley
straw neutral-detergent fibre and alfalfa hay were fermented.
Stanco et al. (21) showed that it was possible to use frozen
inoculum from the caecum of rabbits (stored at 2 188C)
for at least 3 months without affecting gas production,
degradation of organic matter and SCFA production by the
microbiota during in vitro fermentation. In a review aimed
at examining factors that influence microbial activity of the
500

Results and discussion
Use of frozen microbiota
Fig. 2 shows that after 44 weeks of storage at 2 808C, the
composition of the microbiota in terms of viable cells was
not substantially affected, as evidenced by similar banding
patterns on denaturing gradient electrophoresis gels. Furthermore, the stored, frozen samples still contained the microbial
diversity of the fresh faecal sample, indicating that freezing
had minimal influence on the microbiota composition.
The production of SCFA during 196 h of fermentation was
also measured using a fresh microbiota and the same microbiota that had been frozen at 2 808C for 8 d. On comparison,
the fresh and frozen microbiotas showed similar SCFA
production over at least 150 h of fermentation (Fig. 3). Most
notably, during the first 72 h, which is the time period used
in the present study, SCFA production was nearly identical.

400
SCFA (mmol)

British Journal of Nutrition

Schuren et al. (20). DNA was isolated from luminal samples at
the start (t ¼ 0 h) and at the end of the TIM-2 experiments
(t ¼ 72 h). Signals were quantified by calculating the mean
of all pixel values of each spot and calculating the local background about each spot. Signal intensity was dependent on the
position of the probe within the 16S rRNA gene; for that
reason, concentrations of individual bacterial classes could
not be assessed without setting up standard curves using quantitative PCR for each probe. However, signal intensities could
be compared within probe to determine relative changes in
abundance of the bacterial class represented by that particular
probe(20). Because the primary aim was to determine the
propensity of each test carbohydrate to alter individual classes
of bacteria, fold differences between the signals at the initial
and final times were useful for this determination. Standard
deviations were relatively large among runs; therefore, each
replicate was analysed twice.
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300
200
100
0

0

25

50

75

100 125
Time (h)

150

175

200

Fig. 3. Production of SCFA (acetate þ propionate þ butyrate) from a fresh
microbiota (W) and the same microbiota after frozen storage (8 d, 2 808C; X).
Error bars show standard deviation; some error bars are too small to
see; n . 3.
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rumen microbiota, Mould et al. (23) concluded that during storage and sample transport, exposure to air should be excluded.
For this reason, we maintained anaerobosis during storage and
transport using Anaerocult C. These reports, together with the
data provided in Figs. 2 and 3, provided sound evidence that
the use of a frozen microbiota provides results that are comparable to a fresh microbiota for in vitro fermentation studies.

British Journal of Nutrition

SCFA production
SCFA may be of particular importance to colonic health. They
reduce colonic pH, thereby inhibiting the growth of some
opportunistic, pathogenic bacteria(5), decreasing the activity
of co-carcinogenic enzymes such as glucuronidases, glycosidases and 7a-hydroxylases(24,25). Butyrate, one of the SCFA
produced during fermentation, may be especially important
in IBD. In vitro studies have revealed that butyrate suppresses
the immuno-inflammatory response by inhibiting activation of
the transcription factor NF-kB(26) and its downstream products
like pro-inflammatory cytokines TNF and IL-12 as well as
up-regulating the production of the anti-inflammatory cytokine
IL-10(8). Patients treated with butyrate enemas have shown
decreased inflammation due to a reduction in macrophages
positive for activated NF-kB(27).
Patients with IBD have not only shown decreased SCFA
production(28), they may also have impaired ability to harvest
their beneficial effects. Higher concentrations of sulphatereducing bacteria have been reported in patients with IBD
compared with controls(29). An increase in sulphate-reducing
bacteria increases hydrogen sulphide production, which
blocks colonocyte oxidation of butyrate(30). Therefore, dietary
fibres that can increase butyrate production by enhancing
growth of butyrate producing bacteria, or fibres that can
improve butyrate utilisation by inhibiting the growth of
sulphate-reducing bacteria may be helpful in alleviating
colonic inflammation.
When comparing among faecal microbiotas grown on
starch-entrapped microspheres, the healthy microbiota
produced more butyrate than microbiotas from IBD stools
(Table 3), demonstrating impaired butyrate production by
faecal microbiota in IBD patients. This was most pronounced
in the inactive CD microbiota. In faecal microbiota grown on
Table 3. Butyrate and total SCFA production from healthy, inactive
Crohn’s disease (CD) and active ulcerative colitis (UC) microbiotas
when administered starch-entrapped microspheres (SM) or fructooligosaccharides (FOS); values reported as mmol produced per amount
of carbohydrate administered
Microbiota source/carbohydrate source
Healthy
SM
FOS
Inactive CD
SM
FOS
Active UC
SM
FOS
a,b,c,d

Butyrate

Total SCFA

FOS, only the microbiota from patients with inactive CD
showed significant inhibition. Of note is that starch-entrapped
microspheres resulted in significantly higher butyrate
production than FOS when fermented with the healthy and
active UC faecal microbiotas.
Total SCFA production was similar when comparing
between carbohydrate sources, except when the faecal microbiota from active UC were used (Table 3). In this case,
starch-entrapped microspheres produced significantly more
SCFA. Moreover, starch-entrapped microspheres were able
to induce a total SCFA production in this diseased microbiota
that were similar to the healthy faecal microbiota. The same
was not true for FOS.
During the adaptation period (t ¼ 2 16– 0 h), the faecal
microbiota were fed a standard ileal efflux medium, which
contained a mixture of carbohydrates that approximates the
range of substrates that colonic bacteria may be exposed to
under normal conditions(17). Therefore, the molar ratios of
SCFA produced during this time period could be compared
to the ratios at the end of the test period (t ¼ 72 h) to determine whether there was a shift in the molar ratios of
SCFA produced. In particular, an increase in the molar
proportion of butyrate produced would suggest an increase
in butyrate producing bacteria, which may be beneficial due
to the anti-inflammatory nature of butyrate.
In the healthy faecal microbiota, a significant increase in the
proportion of butyrate produced was only experienced when
the faecal microbiota were exposed to starch-entrapped
microspheres (Fig. 4; with a concomitant decrease in acetate
production, data not shown). The microbiota from patients
with inactive CD showed a shift toward butyrate production
with both starch-entrapped microspheres and FOS (with concomitant decrease in acetate production, data not shown),
while that of active UC showed no significant shift toward
butyrate production.
Thus, in light of the trophic effects of SCFA, and in particular butyrate, on the colon, our data suggest that starchentrapped microspheres may be more beneficial than FOS to
promote gut health in healthy subjects and to promote antiinflammatory milieu in the colon of patients with active UC.

50
Butyrate (mol%)
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A

40
BC

B

B

B
B

30
CD
20

D

10
97·1a
57·1b,c

197a
170a,b

21·0d
23·4d

109c
85·9c

72·0b
38·8c,d

203a
125b,c

Mean values within a column with unlike superscript letters were significantly
different (P,0·05).

E
0

SIEM SM FOS SIEM SM FOS SIEM SM FOS

Fig. 4. Molar percentage of butyrate (of total SCFA) produced from healthy
(B), inactive Crohn’s disease ( ) and active ulcerative colitis (A) microbiotas
when administered a standard ileal efflux medium (SIEM, Table 2) during the
adaptation period (t ¼ 2 16–0 h, Fig. 1) compared with starch-entrapped
microspheres (SM) or fructo-oligosaccharides (FOS) during the test period
(t ¼ 0– 72 h, Fig. 1); bars marked with the different capital letters are
significantly different (P, 0·05).

Fermentation of starch-entrapped microspheres

As mentioned, the TIM-2 system more closely approximates
the proximal rather than the distal colon because the microbiotas are constantly supplied with test carbohydrates during
fermentation. To approximate conditions that may occur in
more distal regions of the colon, the feeding line of the TIM2 system was shut off during the last 4 h of fermentation.
Fig. 5 shows the changes in pH during the last 4 h of fermentation when starch-entrapped microspheres and FOS were
inoculated with the faecal microbiota from healthy individuals
or patients with IBD. SCFA from the saccharolytic fermentation cause a decrease in pH that is detected by the automatic
titrator that prevents the pH from dropping below 5·8 by
addition of sodium hydroxide. Therefore, a jagged line indicates
the saccharolytic fermentation, and the more jagged the line
(crests closer together), the more rapid the fermentation rate.
During the first hour after the feeding line was shut off
(68 –69 h), all the samples showed saccharolytic fermentation.
The starch-entrapped microspheres clearly showed a less
jagged line than FOS, indicating slower fermentation. The
faecal microbiota from healthy subjects showed continued
the saccharolytic fermentation after the feeding line was
shut off (t ¼ 69– 72 h) when grown on starch-entrapped
microspheres. Conversely, FOS showed a gradual increase in
pH during this time period, which is indicative of a shift

(a)

6·8
6·3
5·8
5·3

(b)

pH
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Fermentation rate and pH changes

6·8
6·3
5·8
5·3

(c)

6·8

toward putrefactive fermentation, which results in NH3 production. This supports our previous study showing slow digestion and fermentation of the starch-entrapped microspheres(12)
and suggests this material could provide beneficial fermentable carbohydrates in the distal colon, whereas FOS would not.
As with the healthy microbiota, the microbiota from IBD
patients showed continuous fermentation when fermented
with starch-entrapped microspheres (Fig. 5). The large peaks
for the active UC microbiota when fed starch-entrapped
microspheres were due to inadequate mixing. For an unknown
reason, when starch-entrapped microspheres were fermented
with the active UC microbiota, the slurry became very thick
and the mixing laboured. Although this situation was not
ideal, this curve still did not show a gradual upward trend
(as seen with FOS), indicating the occurrence of saccharolytic
fermentation with the starch-entrapped microspheres.
In contrast to starch-entrapped microspheres, the microbiota
from patients with IBD when incubated with FOS, showed
more pronounced increases in pH during the final 4 h of
fermentation compared with the stool from healthy individuals. This suggests that slowly fermentable dietary fibres,
such as starch-entrapped microspheres, may be of particular
importance in IBD due to their ability to maintain a low pH
during prolonged fermentation.
Fermentation rate is important for the maintenance of gut
health. As carbohydrates are fermented and their amount
diminishes, putrefactive fermentation becomes significant,
leading to an increase in pH due to lack of SCFA and
production of NH3 (10). The higher pH may allow the proliferation of undesirable bacteria(5). The distal colon also contains
higher concentrations of toxic metabolites(10) due to fermentation of protein instead of carbohydrate. These undesirable
conditions in the distal colon may exacerbate inflammation
and explain the high rate of colonic neoplasia in left side of
the colon. Thus, improving colonic milieu in the distal colon
by delivering slow fermentable carbohydrate could be a
beneficial intervention for promotion of gut health and prevention of colonic diseases like colonic polyps and cancer in
healthy subjects as well as controlling colonic inflammation
in inflammatory disorders of colon like UC. Our data provide
compelling evidence that starch-entrapped microspheres are
the ideal substrate to achieve this goal, although further
in vivo, long-term studies in healthy subjects and patients
with IBD are required to confirm these gut-health promoting
effects of starch-entrapped microspheres.
Initial composition of the microbiotas from healthy individuals
and patients with inactive Crohn’s disease and active
ulcerative colitis

6·3
5·8
5·3
68

1519

69

70
Time (h)

71

72

Fig. 5. Changes in pH during the last 4 h of fermentation (when the feeding
line had been shut off) of faecal microbiotas from healthy individuals (a),
patients with inactive Crohn’s disease (b) or active ulcerative colitis (c) that
had been previously fed starch-entrapped microspheres (—) or fructooligosaccharides ( ).

Table 4 shows the initial (t ¼ 0 h) fold differences among the
diseased and healthy faecal microbiotas of some of the major
genera of bacteria found in the large intestine(31,32). Therefore,
changes in these classes of bacteria would likely represent a
change in the gut metabolism as a whole. The microbiota
from patients with inactive CD displayed far weaker signals
for Bacteroides, Clostridium and Eubacterium compared
with the healthy microbiota. In contrast, the faecal microbiota
from patients with active UC displayed only slightly different
signals for these three genera of bacteria compared with the
faecal microbiota from healthy individuals. This suggests
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Table 4. Fold differences in signal for select bacterial classes in the
initial microbiota from patients with inactive Crohn’s disease (CD) or
active ulcerative colitis (UC) compared with the healthy microbiota;
values reported as fold difference from healthy faecal microbiota, with
negative numbers indicating a lower signal in the diseased stool and a
positive number signifying a higher signal in the diseased stool
Classification

Inactive CD

Active UC

General bacteria
Bacteroides
Bifidobacterium
Clostridium
Enterococcus
Escherichia
Eubacterium
Fusobacterium
Lactobacillus
Streptococcus
Veillonella

2 2·21***
2 19·3***
2 12·4***
2 9·23***
2 1·47
2 1·45
2 5·77***
1·67
2 1·09
2 1·14
1·00

2 1·58**
1·89***
2 4·23***
2 1·03
1·23
2 3·21*
2 1·74*
10·9***
1·00
2 1·32
1·55***
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Mean values were significantly different from those of healthy microbiota: *P,0·05,
**P, 0·01, ***P, 0·001.

that microbiota from patients with active UC more closely
resembled the healthy microbiota than did the inactive CD
microbiota, as these three genera of bacteria represent the
major proportion of the gut microbiota as a whole(33).
Additionally, these are the most important butyrate producers
in the gut. The fact that these genera were so much higher in
the healthy and active UC microbiota compared with inactive
CD at least partially explains why butyrate production was so
low in the inactive CD microbiota (Table 3).
For the probiotic genera Lactobacillus and Bifidobacterium,
no substantial differences were found in the concentrations
of Lactobacillus among microbiotas, but the healthy microbiota
had a far greater quantity of Bifidobacterium than the microbiota from active UC and inactive CD patients. These genera
of bacteria are reported to be beneficial to gut health(4);
and their lack may be related to the diseased condition.

When comparing the general bacterial signals, the
microbiota from patients with inactive CD showed a 2-fold
lower concentration than that of healthy individuals. However,
signals from a number of the genus probes shown in Table 4
were substantially lower for the inactive CD microbiota
compared with the healthy stool. In particular, the major
genera, Bacteriodes, Clostridium and Eubacterium, were far
more than 2-fold lower. This suggests that many of the
bacteria in the inactive CD microbiota belonged to genera
not represented in Table 4. This supports the findings of
Seksik et al. (34), who demonstrated that a high percentage
(30 %) of the dominant microbiota in CD belongs to unusual
phylogenetic groups.

Changes in the faecal microbiota of healthy subjects during
fermentation
After 72 h of fermentation, FOS induced a major increase in
the concentration of Eubacterium in faecal microbiota from
healthy subjects, whereas starch-entrapped microspheres did
not (Table 5). While Eubacteria are important butyrate
producers(35), the significantly higher butyrate production
from the healthy microbiota when administered starchentrapped microspheres compared with FOS (Table 3)
suggests that starch-entrapped microspheres must have
increased the growth of other butyrate producing bacteria
more than FOS increased the growth of Eubacterium.
Concentrations of Streptococci were decreased with starchentrapped microspheres, but left largely unchanged with
FOS (Table 5). Prior studies reported that Streptococcus
species exhibit mixed effects on the colonic environment.
While some species, such as Streptococcus agalactiae and
Streptococcus bovis, display negative effects on colonic
melieu(36 – 38), other species such as S. salivarius, show
positive characteristics(39,40). In the present study, of these

Table 5. Fold changes in the signals of selected bacterial classes in the healthy, inactive Crohn’s disease (CD) and active ulcerative colitis (UC)
microbiotas after 72 h of fermentation with starch-entrapped microspheres (SM) or fructo-oligosaccharides (FOS); values reported as fold difference
from the initial respective faecal microbiota, with negative numbers indicating a lower signal after fermentation, and positive numbers signifying a higher
signal after fermentation
Healthy
Bacterial group
General bacteria
Bacteroides
Bacteroides fragilis
Bacteroides vulgatus
Bifidobacterium
Clostridium
Clostridium butyricum
Clostridium perfringens
Enterococcus
Escherichia
Eubacterium
Fusobacterium
Lactobacillus
Streptococcus
Streptococcus agalactiae
Streptococcus bovis
Streptococcus salivarius
Veillonella

Inactive CD

Active UC

SM

FOS

SM

FOS

SM

FOS

2 1·18
1·07
2 6·47***
1·32
1·04
2 6·67***
2 5·20***
2 7·83
2 1·64
2 20·7*
1·15
2·80
2 1·09
2 2·48**
2 1·20
2 1·12**
2 8·46**
1·00

2 1·18
2 1·16
2 2·44**
2 3·44*
1·09
2 6·00***
2 5·20***
2 8·55
2 2·76**
2 37·2*
7·19***
5·33***
2 1·09
2 1·19
2 1·09
2 1·07
2 1·37
1·00

1·00
5·96*
1·62
5·94
2 3·43**
1·54
1·17
2 1·15*
2 1·66
2 24·1*
1·46
2 1·79
1·27
1·07
1·95
2·06
2 2·53
1·00

1·18
15·0***
5·38***
16·3**
2 3·60**
2·54**
2·08***
2 1·12
2 2·53
2 22·6*
13·5***
1·16
1·09
1·35
3·41
2·12
2 1·56
8·18**

2 1·22
2 1·89**
2 2·37***
2 2·09*
2 1·50
2 5·85**
2 4·38*
2 10·3***
2 4·42**
2 11·6
1·81
2 10·9**
2 1·09
2 1·31
2 1·73
2 3·31
2 1·18
2 1·06

1·24*
2 2·59***
2 11·8***
2 3·07**
2 3·52***
2 3·66**
2 3·18*
2 36·4***
2 2·45*
2 11·6
2·16
2 2·98
1·00
2·13**
2·11
1·74
1·91
13·4**

Mean values were significantly different from those of initial microbiota: *P,0·05, **P,0·01, ***P,0·001.
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three species, S. bovis decreased slightly and S. salivarius
decreased substantially after fermentation with starchentrapped microspheres. This suggests that FOS has greater
benefit than starch-entrapped microspheres with respect to
Streptococcus growth in the healthy faecal microbiota.
Clostridium concentrations were substantially affected by
the test carbohydrates to about the same degree for the two
treatments (Table 5). Clostridium is sometimes recognised as
a harmful or undesirable genus of the gut microbiota(4). For
example, Clostridium difficile produces a toxin that causes
colitis-like inflammation(41), and infection with C. difficile
exacerbates inflammation in patients with IBD(42). Unfortunately, we did not have a probe for C. difficile and were
unable to determine how the test carbohydrates affected this
bacterium. Two Clostridia that we did have probes, for
Clostridium perfringens and Clostridium butyricum, were
decreased by starch-entrapped microspheres and FOS by
roughly the same degree. C. perfringens may have detrimental
effects, suggested by significantly more C. perfringens found
in faecal samples from patients with IBD compared with
controls(43). In contrast, C. butyricum may be beneficial
through its high SCFA (including butyrate) production and
ability to alleviate dextran sodium sulphate-induced colitis in
rats(44). In fact, many clostridia are major contributors to the
colonic butyrate pool(28), which indicate that they may have
an anti-inflammatory effect.
Escherichia concentrations were decreased during fermentation on starch-entrapped microspheres and FOS (Table 5).
Escherichia, like clostridia, have mixed effects on the
colonic environment, with some species exhibiting benefits
and others exhibiting detrimental effects(4). While a virulent
strain of Escherichia coli (adherent-invasive E. coli) has
been isolated from the ileal mucosa of rats with CD(45), and
high concentrations of E. coli have been associated with colitis
in rats(46), other strains of E. coli (e.g. Nissle 1917) are
established probiotics(47).
In the healthy microbiota, the concentrations of Bifidobacterium and Lactobacillus were unaffected during fermentation,
independent of carbohydrate source (Table 5). It is surprising
that there was not an increase in Bifidobacterium on FOS,
as FOS is known to be bifidogenic(48). A likely explanation
is that the concentration of Bifidobacterium in the faecal
microbiota community in healthy subjects, as suggested by
Table 4, was initially quite high. If such was the case, previous
research has demonstrated that it is almost impossible to then
increase Bifidobacterium even further(49).
Changes in the microbiota from patients with inactive Crohn’s
disease during fermentation
The faecal microbiota from patients with inactive CD showed
a substantial increase in Bacteroides concentration during
fermentation (Table 5). Because faecal microbiota from
patients with inactive CD had an extremely low concentration
of Bacteroides at the initial time compared with the healthy
microbiota (Table 4), an increase would represent a shift
toward the healthy microbiota; thus suggesting a beneficial
shift. The fact that FOS was able to increase Bacteroides
more than starch-entrapped microspheres suggests that
FOS was more desirable than starch-entrapped microspheres
in this regard; however, some species of Bacteroides are
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undesirable. For instance, Bacteroides fragilis is found in
much larger numbers in the mucosal biofilm in patients with
CD compared with healthy individuals, and thus may play a
role in the pathogenesis of this disease(50). Also, Bacteroides
vulgatus expresses a membrane protein that induces
inflammation(51). There was an increase in B. fragilis during
fermentation with FOS, whereas no change was observed
with starch-entrapped microspheres (Table 5). B. vulgatus
were increased with both carbohydrate treatments, but only
FOS showed a significant increase. Therefore, starchentrapped microspheres may be superior to FOS at preventing
the growth of potentially harmful Bacteroides species.
Eubacterium and Veillonella concentrations were also
affected differently by starch-entrapped microspheres compared with FOS. Eubacterium concentration was increased
during fermentation with FOS, while no change was observed
with starch-entrapped microspheres (Table 5). As mentioned,
the major benefit of Eubacterium is high butyrate
production(35), yet the production of this metabolite was not
significantly different among starch-entrapped microspheres
and FOS when fermented with the microbiota from inactive
CD patients (Table 3). This indicates that the increase in the
concentration of Eubacterium seen with FOS must not have
exceeded the increase in other butyrate producers induced
by starch-entrapped microspheres. Veillonella was increased
with FOS, whereas starch-entrapped microspheres had little
effect. It is noteworthy that Veillonella is a harmful gut
genus(4), because it is not saccharolytic and produces NH3
and hydrogen sulphide(52). Our finding suggests that starchentrapped microspheres may be preferred over FOS by
limiting growth of Veillonella.
Starch-entrapped microspheres and FOS induced similar
effects on Enterococcus, Escherichia and Bifidobacterium
concentrations (Table 5). Enterococcus signals were not
increased with either carbohydrate. This is likely beneficial
because high concentrations of Enterococcus have been
associated with colitis in rats(46) and Enterococcus facialis
leads to distal colitis in mice(53). Escherichia concentrations
were decreased with starch-entrapped microspheres and
FOS. The mixed effects that this may have on the gut microbiota have been discussed earlier. Shifts in Bifidobacterium
were unexpected. Significant decreases in this genus were
observed when the microbiota from patients with inactive
CD was exposed to starch-entrapped microspheres or FOS.
One possible explanation is that stool microbiota community
in patients with CD had an initially low concentration of
Bifidobacterium; therefore, it is likely that these bacteria
were unable to compete with the other bacteria for substrate,
and thus were unable to proliferate. Alternatively, this
decrease may simply be due to differences among healthy
and diseased microbiota, i.e., a carbohydrate that is beneficial
for one type of microbiota, may not be beneficial for another.
Changes in the microbiota from patients with active ulcerative
colitis during fermentation
Starch-entrapped microspheres and FOS both resulted in similar decreases in Bacteroides signals during fermentation
(Table 5). Unlike the microbiota from inactive CD, the microbiota from patients with active UC showed a much higher
concentration of Bacteroides than the faecal microbiota in
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healthy subjects before fermentation; therefore, a decrease in
Bacteroides after fermentation may be beneficial. Of the two
detrimental Bacteroides that we had probes for, B. fragilis
and B. vulgatus, FOS induced far greater decreases than
starch-entrapped microspheres. This suggests that FOS may
result in more favourable changes in Bacteroides than
starch-entrapped microspheres in active UC due to more
substantial decreases in these potentially harmful species
belonging to this genus.
Clostridium concentrations were affected largely to the
same extent regardless of carbohydrate source. Within the
clostridial genera, the beneficial bacterium, C. butyricum,
and the detrimental bacterium, C. perfringens, were also
substantially decreased by both the carbohydrates (Table 5).
The effects of starch-entrapped microspheres and FOS were
different with respect to their influence on Enterococcus,
Fusobacterium, Streptococcus and Veillonella. Both the
carbohydrates decreased Enterococcus concentrations, but
FOS only showed a 2·5-fold decrease, while starch-entrapped
microspheres showed a 4·5-fold decrease (Table 5). In light
of the possible detrimental effects of Enterococcus on gut
health(46,53), these data would suggest a greater benefit
of starch-entrapped microspheres compared with FOS.
Fusobacterium is another genus of bacteria that is likely
detrimental to gut health; Fusobacterium varium has been
suggested as a causative agent for UC(54). Even though we
did not have a probe for this specific bacterium, a decrease
in its genera may be beneficial. Starch-entrapped microspheres decreased the concentration of this genus, while
FOS did not significantly affect Fusobacterium concentrations. Streptococcus increased with FOS and exhibited no
substantial change with starch-entrapped microspheres; however, no change in the signals from individual Streptococcus
species probes was observed. Veillonella was unchanged by
starch-entrapped microspheres, but exhibited an increase
with FOS. These data indicate that starch-entrapped microspheres may be better than FOS at preventing the proliferation
of this purported harmful bacterial genus(4).
There were unexpected changes in Bifidobacterium.
Starch-entrapped microspheres did not substantially affect
the Bifidobacterium concentration, but FOS decreased its
concentration (Table 5). This supports the conclusions from
the inactive CD microbiota that Bifidobacterium were unable
to compete with other bacteria for substrate, or that a carbohydrate that is beneficial in one case may not be beneficial
in all instances.
Conclusions
Although the aetiology of IBD remains unknown, it is now
thought that gut microbiota play a key role in initiation and/
or progression of gut inflammation and associated tissue
injury. For example, it is known that luminal bacteria of
IBD patients differ significantly from healthy subjects(31),
and the abnormal microbiota are likely to play a role in the
disease progression(3). Prebiotics and other dietary fibre
substrates may be able to correct microbial abnormalities in
IBD by selectively stimulating the growth of beneficial
bacteria(4). In the present study, starch-entrapped microspheres, with long lasting and controlled fermentation
properties, were tested against FOS, a known prebiotic, in

regard to their influence on fermentation profiles and the
stool microbiota of healthy subjects and patients with IBD.
Starch-entrapped microspheres showed clear advantages
over FOS with respect to fermentation rate. Starch-entrapped
microspheres fermented more slowly than FOS, as indicated
by continued production of SCFA during the final starvation
period (t ¼ 70 –72 h). This supports our previous findings(12)
and suggests that, unlike FOS, starch-entrapped microspheres should provide fermentable substrate into the distal
colon, where carbohydrates, and consequently the beneficial
fermentative metabolites, SCFA and particularly butyrate,
are generally scarce.
Starch-entrapped microspheres resulted in higher butyrate
production than FOS when fermented with the stool microbiota from healthy subjects and the stool microbiota from
patients with active UC. This may have particular application
for treatment of UC flare-ups and maintenance of remission
due to the anti-inflammatory properties of butyrate. However,
starch-entrapped microspheres did not outperform FOS in
every aspect. For example, FOS resulted in lower concentrations of the potentially harmful bacteria, B. fragilis and
B. vulgatus, after fermentation compared with starchentrapped microspheres. Nevertheless, FOS resulted in
higher concentrations of other potentially harmful bacteria:
Enterococcus; Fusobacterium; Veillonella.
Starch-entrapped microspheres also showed benefits on
the microbiota profile of patients with inactive CD. After fermentation with starch-entrapped microspheres, we noted lower
concentrations of the potentially harmful Bacteroides species,
B. fragilis and B. vulgatus, in the stool microbiota from patients
with inactive CD compared with fermentation with FOS.
Additionally, while FOS enhanced the growth of the harmful bacterial genus, Veillonella, starch-entrapped microspheres did not.
One limitation of the present study is that we used two
different types of IBD to study active and inactive states of
inflammation. Although UC and CD are inflammatory diseases
of intestine and have many similar clinical and mechanistic
features, they are two different types of inflammatory
disorders. Our original aim was to compare the healthy microbiota to both active and inactive CD and UC. Unfortunately,
during faecal collection, many patients were unable to produce
a stool and thus we were unable to collect stools from all the
groups. Since our primary aim was to compare the impact of
fermentable substrates on microbiota composition and SCFA
production between the healthy subjects and those with
active and inactive colonic inflammation, we believe the use
of inactive CD and active UC still yielded useful results.
Our findings suggest that different fermentable substrates
affect the microbiota from individuals in healthy and diseased
states differently, and that starch-entrapped microspheres
induce a higher production of beneficial fermentation products
and a decrease in the growth of potentially harmful gut
bacteria more than FOS. Further in vivo studies are needed to
confirm these findings and to determine whether starch-entrapped
microspheres can promote gut health in healthy subjects and
attenuate colonic inflammation in IBD and promote remission.
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